Physician

Michael R Brooks, MD

According to 2025 Medicare claims, Michael Brooks, MD (NPI: 1942358403) practices nephrology in the Sheboygan, WI market, with the plurality of this provider's patient population coming from Sheboygan, WI. This provider's primary affiliated billing organization is AURORA MEDICAL GROUP, INC. (NPI: 1427271378; TIN: 391678306) and primary practice location at 53081-3129. Brooks is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033) and Accountable Care Organization of Advocate Aurora Health, LLC (ACO ID: D0260), participating under both the MSSP and REACH models.

Brooks' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 375 traditional Medicare patients, billed 13,025 HCPCS/CPT codes, and received $106,338 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 4,535 prescription claims across 761 beneficiaries totaling $415,341 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 218 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $207,256 to $106,338. Similarly, Part D prescription costs have declined steadily, from $615,415 to $415,341. In contrast, DME billing represents a smaller volume and rose steadily, from $4,502 to $9,523.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	591	9,201	$207,256
2016	535	13,687	$188,860
2017	474	17,006	$185,860
2018	457	22,296	$158,456
2019	465	14,014	$143,302
2020	421	12,050	$114,573
2021	413	6,039	$128,738
2022	393	3,970	$95,485
2023	382	8,636	$104,198
2024	375	13,025	$106,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	510	6,616	$615,415
2016	579	5,945	$582,743
2017	553	6,710	$657,648
2018	568	6,533	$621,378
2019	582	5,399	$471,409
2020	601	5,068	$448,335
2021	551	4,441	$457,656
2022	763	4,603	$391,805
2023	954	4,908	$458,294
2024	761	4,535	$415,341

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	29	411	$65,128
2016	27	302	$29,546
2017	40	438	$30,033
2018	40	473	$41,747
2019	43	486	$59,665
2020	23	469	$61,968
2021	20	414	$46,579
2022	18	375	$29,757
2023	N/R	202	$15,710
2024	N/R	218	$11,463

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	30	73	$250
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	52	52	$110
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	37	41	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	279	474	$83
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	37	72	$54

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	41	2,469	$45,104
Eliquis	Apixaban	45	1,874	$36,462
Jardiance	Empagliflozin	21	1,242	$25,560
Januvia	Sitagliptin Phosphate	21	1,290	$24,138
Tresiba Flextouch U-100	Insulin Degludec	15	766	$19,444

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	11	$6,319
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	11	$997
J7515	Cyclosporine, oral, 25 mg	N	N/R	11	$854
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	56	$712
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	20	$492

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Michael R. Brooks, MD?

Tedicare shows public-source Medicare data for Michael R. Brooks, MD (NPI 1942358403), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael R. Brooks, MD have ACO affiliation data?

Michael R. Brooks, MD is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033) and Accountable Care Organization of Advocate Aurora Health, LLC (REACH, ACO ID D0260).

What billing organization is linked to Michael R. Brooks, MD?

Michael R. Brooks, MD is linked to AURORA MEDICAL GROUP, INC. (billing NPI 1427271378) in the available physician profile data.

Does Michael R. Brooks, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.